louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06151717: A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
Official title: PRAGMMATIC: A Comparative Clinical Trial to Determine the BEST Initial Therapy for Multiple Myeloma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Myeloma
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-11-30
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with previously untreated multiple myeloma

Brief summary: This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.

Detailed description: PRIMARY OBJECTIVE:

I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM.

OUTLINE: This is an observational study.

Patients have their medical records reviewed on study.

Eligibility criteria: Inclusion Criteria:

* Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone)
* No prior treatment for myeloma
* Not receiving concurrent treatment for another active malignancy
* No more than 3 months from start of treatment

Exclusion Criteria:

* Does not meet all inclusion criteria

Primary outcomes:
measure: Overall survival
timeFrame: Every 3 months, up to 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
city: La Crosse
country: United States
facility: Mayo Clinic Health System-Franciscan Healthcare
state: Wisconsin
Study officials:
affiliation: Mayo Clinic in Rochester
name: Shaji K. Kumar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05248217: Burnout, Covid 19, Smarthphone Addiction
Official title: Assessment of Burnout Syndrome and Smartphone Addiction in Healthcare Workers Actively Working During the COVID-19 Pandemic
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burn Out
Addiction, Smartphone
Keywords: burnout
covid-19
healthcare workers
smarthphone addiction
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2022-02-21
Enrollment: 183
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: We investigate burnout syndrome and smartphone addiction in healthcare workers, including doctors, nurses, medical secretaries, security guards, and cleaning staff, who have been actively working from the beginning of the COVID-19 pandemic. target population included 1190 healthcare workers, from which a total of 183 agreed to participate in the study and met the inclusion criteria for participation. A sociodemographic data form, the Maslach Burnout Inventory, and the Smartphone Addiction Scale-Short Version were used as the data collection tools.

Detailed description: Significant differences in burnout syndrome were found in doctors and nurses. A relationship was observed between emotional burnout (EB), desensitization, and smartphone addiction, as well as between doctor and nurse group, and smartphone addiction. According to the linear regression analysis, it was determined that 17% of the change in the smartphone addiction score was related to age and 16% to master education level.Doctors and nurses experience the highest rate of burnout syndrome and smartphone addiction, and EB and desensitization were more likely to have smartphone addiction. Age and high education can affect smarthphone addiction

Eligibility criteria: Inclusion Criteria:

1. Being older than 18 years of age
2. Working as medical staff
3. Having no systemic or psychiatric disorders
4. No psychotropic substances use
5. No alcohol or substance use

Exclusion Criteria:

-

Primary outcomes:
measure: maslach burnout scale
timeFrame: 30 minutes
Secondary outcomes:
measure: smarthphone addiction scale
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Rize
country: Turkey
facility: Recep Tayyip Erdogan University
state: None Selected
Study officials:
References:
Clinical trial NCT04823117: The Effect of Music on Quality of Life in Fibromyalgia Patients
Official title: The Effect of Therapeutic Use of Music on Quality of Life in Fibromyalgia Patients: a Randomized Controlled Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fibromyalgia
Music Therapy
Quality of Life
Keywords: fibromyalgia
music therapy
fibromyalgia Impact Questionnaire
Lead sponsor: Diskapi Teaching and Research Hospital
Sponsor class: OTHER
First posted: 2021-03-30
Enrollment: 101
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with fibromyalgia, admitted to polyclinics

Brief summary: This study's aim was to determine the effect of music therapy on symptoms and functions in patients with fibromyalgia syndrome (FMS).

Detailed description: This study's aim was to determine the effect of music therapy on symptoms and functions in patients with fibromyalgia syndrome (FMS). Women diagnosed with FMS for at least 6 months included in the study. 16 patients were in the music treatment group and 51 patients were in the control group. Patients in music treatment group were given a music CD which includes nature sounds recommended by the Turkish Psychological Association. The patients were evaluated with Fibromyalgia Impact Questionnaire (FIQ) before and after the treatment.

Eligibility criteria: Inclusion Criteria:

* Female patients over the age of 18
* Being diagnosed as FMS according to 2010 American College of Rheumatology (ACR) criteria for FMS
* Having the diagnosis of FMS at least six months

Exclusion Criteria:

* Patients with hearing problems, pregnancy, another accompanying central sensitization syndrome or schizophrenia
* Patients with psychiatric illness
* Patients whose pharmacological treatment for FMS changed within the last three months
* Patients without a listening device
* Patients who do not have a cognitive level to answer the questions in the scale

Primary outcomes:
measure: Fibromyalgia Impact Questionnaire
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Merkez
country: Turkey
facility: Çağla Özdemir
state: Kütahya
Study officials:
affiliation: Dışkapı Eğitim ve Araştırma Hastanesi
name: Çağla Özdemir
role: PRINCIPAL_INVESTIGATOR
References:
citation: Garza-Villarreal EA, Wilson AD, Vase L, Brattico E, Barrios FA, Jensen TS, Romero-Romo JI, Vuust P. Music reduces pain and increases functional mobility in fibromyalgia. Front Psychol. 2014 Feb 11;5:90. doi: 10.3389/fpsyg.2014.00090. eCollection 2014.
citation: Alparslan GB, Babadag B, Ozkaraman A, Yildiz P, Musmul A, Korkmaz C. Effects of music on pain in patients with fibromyalgia. Clin Rheumatol. 2016 May;35(5):1317-21. doi: 10.1007/s10067-015-3046-3. Epub 2015 Aug 6.
citation: Korhan EA, Uyar M, Eyigor C, Hakverdioglu Yont G, Celik S, Khorshid L. The effects of music therapy on pain in patients with neuropathic pain. Pain Manag Nurs. 2014 Mar;15(1):306-14. doi: 10.1016/j.pmn.2012.10.006. Epub 2013 Jan 31.
Clinical trial NCT02390817: Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup
Official title: Effect of Sugammadex in Wakeup Procedure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Spinal Curvatures
Lead sponsor: Cukurova University
Sponsor class: OTHER
Collaborators: name: Private Ortopedia Hospital, Seyhan Adana
First posted: 2015-03-18
Enrollment: 60
Sex: ALL
Minimum age (years): 10
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The study will be performed to evaluate motor response and awareness with using sugammadex during wakeup procedure in spine surgery. The investigator's goal is to investigate the effect of sugammadex on the state of consciousness and motor-somatosensorial evoked potentials.

Detailed description: Between 10-25 age, American Society of Anesthesiologist clinical status(ASA) I-II, 60 patient which will be performed spine surgery in orthopedics clinic will be enrolled in this study. Patient will be randomized into two group that include 20 patient. General anesthesia will be administered by Totally intravenous anesthesia (TIVA) with propofol and remifentanyl for all patients. Two groups will be monitored with BIS (bispectral index), TOF (train-of-for) MEP (motor evoked potential) and SSEP (somatosensorial potential). During wakeup procedure, in group S, TIVA will be stopped and 2 mg/kg of sugammadex will be given intravenously. BIS, TOF, MEP, SSEP will be measured. In group N, TIVA will be stopped and 0.04 mg/kg of neostigmine will be given. Also BIS, TOF, MEP, SSEP will be measured. Sugammadex will be given group S and Neostigmine will be given group N at the end of the operation. At postoperative sixth hour, the investigators will visit all the patients and ask standard questions about intraoperative wakeup procedure.

Eligibility criteria: Inclusion Criteria:

* American society of anesthesiologists (ASA) physical status I-II patients
* spine surgery
* 10-25 age

Exclusion Criteria:

* ASA III and above
* Patient refusal
* neuromuscular disease

Primary outcomes:
measure: Time to consciousness
timeFrame: 30 min
Secondary outcomes:
measure: To assess Motor Evoked Potential values
timeFrame: 4 hours
measure: To assess Somatosensorial Evoked Potential values
timeFrame: 4 hours
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Ebru Biricik
state: Sarıçam
city: Adana
country: Turkey
facility: Çukurova University
state: Çukurova
Study officials:
affiliation: Medical Director
name: Ebru Biricik
role: STUDY_DIRECTOR
References:
citation: Adamus M, Hrabalek L, Wanek T, Gabrhelik T, Zapletalova J. Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. J Anesth. 2011 Oct;25(5):716-20. doi: 10.1007/s00540-011-1209-1. Epub 2011 Aug 13.
Clinical trial NCT05772117: A RCT Evaluating an Online Intervention in Increasing Pneumococcal Vaccination Among Older Adults
Official title: A Randomized Controlled Trial Evaluating a Theory-based Online Intervention Via Fully Automated Chatbot in Increasing Pneumococcal Vaccination Among Community Dwelling Individuals Aged ≥65 Years
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vaccination Refusal
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2023-03-16
Enrollment: 374
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To evaluate the relative efficacy of an online intervention based on the Trans-theoretical Model delivered by a fully-automated Chatbot with natural language processing functions versus a control in promoting pneumococcal vaccination uptake among Hong Kong people aged ≥65 years. A total of 374 participants will be randomized evenly to either the intervention group or the control group. Participants in the intervention group will receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3. Participants in the control group will receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3. All participants will be followed up 6 and 12 months after completion of the intervention.


Eligibility criteria: Inclusion Criteria:

* aged ≥65 years
* having Hong Kong ID
* Chinese speaking
* have not received any penumococcal vaccination
* willing to be followed up by telephone
* having a smartphone
* able to send and read text/voice messages via smartphone.

Exclusion Criteria:

* blindness or deafness
* not able to communicate with others effectively
* with known contradictions of pneumococcal vaccination
* having been diagnosed with major psychiatric illness
* scored ≤16 in the validated telephone version of the Cantonese Mini-mental State Examination (T-CMMSE).

Primary outcomes:
measure: Pneumococcal vaccination uptake
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Centre for Health Behaviours Research, the Chinese University of Hong Kong
Study officials:
References:
Clinical trial NCT01770717: Assessment of the Potential for Pressure Ulcer Formation
Official title: Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Pressure Ulcer Not Visible
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
Collaborators: name: Beckman Laser Institute University of California Irvine
First posted: 2013-01-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study polpulation will be selected from UCIMC Inpatient care unit

Brief summary: Pressure ulcers are a significant problem in institutionalized, elderly, and critically ill patients. Pressure ulcers result in significant pain, changing quality of life, and often leading to significant morbidity and prolonged hospital stays, and ultimately increased the healthcare cost.

According to the International Pressure Ulcer Prevalence Survey, the prevalence of hospital acquired pressure ulcers in the United States was 13.5% in 2008 and 12.8% in 2009. This survey also indicated that the highest rate of pressure ulcers is in the long term acute care population (22%).

Detailed description: Researchers developed a non-contact optical imaging technology call Spatial Frequency Domain Imaging which can identify the tissue regions that are at risk of developing pressure ulcers prior to development of irreversible tissue damage. The Spatial Frequency Domain Imaging can identify metabolic and biochemical differences in the tissues near bony prominences which are at risk for developing pressure ulcers.

Eligibility criteria: Inclusion Criteria:

* Male or female 18 years of age and older
* Diagnose with potential of pressure ulcers

Exclusion Criteria:

* No potential of pressure ulcers
* Has history of vascular disease in both lower extremities

Primary outcomes:
measure: Formation of Pressure Ulcer
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Orange
country: United States
facility: UCIMC
state: California
Study officials:
affiliation: Beckman Laser Institute, UCI
name: Anthony Durkin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00364117: Remote Presence Timely Discharge Management
Official title: Remote Presence Timely Discharge Management
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Patient Discharge
Keywords: 150 discharges
adults
Internal Medicine
Lead sponsor: Hackensack Meridian Health
Sponsor class: OTHER
First posted: 2006-08-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to integrate Remote Presence technology in order to increase the number of timely patient discharges before 11 am from the medical center.

Detailed description: Reduction in beds coupled with the increased need for health care services has led to a supply and demand struggle or capacity management challenge for health care facilities. This is now recognized as a major public health issue. The impact is readily seen as overcrowding in emergency departments. At present 76% of hospitals' emergency departments (ETDs) are at or over capacity with 33% reporting ambulance diversions, the most common sign of overcapacity within a health care facility. Compounding the physical capacity problem is the "human capacity strain" as admitted patients remain in the ETD for prolonged periods waiting for beds. Delayed admission to patient care units significantly strains the financial resources, impedes "patient flow" ultimately impacting the quality of care, patient satisfaction and the "bottom line." Discharge before 11 am optimizes the availability of hospital beds to meet admission demands thereby avoiding a surge over capacity or "patient back log", ambulance diversions in ETD; the post anesthesia recovery unit, admissions office and critical care units. Conversely competing needs for the attending physician's physical presence off of the hospital premises; off of the unit (private practice and meetings) often delays patient discharge from before 11 am to the afternoon and evening.

Eligibility criteria: Inclusion Criteria:

* Adult patients
* Primary care physicians in internal medicine
* Primary care physicians/practice group with established discharge pattern after 11 am
* Primary care physicians/practice group with fast access digital subscriber line (DSL) 300 kilobytes per second
* Primary care physicians/practice group who have Hackensack Medical Center (HUMC) intranet access from pre-determined location

Exclusion Criteria:

* Non-English speaking patients
* Patients requiring acute level of care on the day of discharge

Primary outcomes:
measure: Timely patient discharge before 11 am
measure: Patient satisfaction
measure: Employee satisfaction
Secondary outcomes:
measure: Employee satisfaction
measure: Physician satisfaction
measure: Financial impact on medical center
Other outcomes:
Locations:
city: Hackensack
country: United States
facility: Hackensack University Medical Center
state: New Jersey
Study officials:
affiliation: Hackensack Meridian Health
name: Joseph Feldman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05159817: Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
Official title: Monocentre, Observational Clinical Study Evaluating the Efficacy and Safety of a Novel Interposition Supraciliary Implant in Glaucoma Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Glaucoma, Open-Angle
Lead sponsor: Ciliatech
Sponsor class: INDUSTRY
First posted: 2021-12-16
Enrollment: 19
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655

Brief summary: The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.

Detailed description: 19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted.

These patients reached 6 months follow-up and the original study had to be interrupted.

This observational study prolonges follow-up to 36 months

Eligibility criteria: Inclusion Criteria:

* All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655

Exclusion Criteria:

* if cannot assist to all future follow-up visits

Primary outcomes:
measure: Assess post-op IOP reduction
timeFrame: 12, 24 and 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Yerevan
country: Armenia
facility: Malayan Center
Study officials:
References:
Clinical trial NCT04660617: A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
Official title: A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prostate Cancer Metastatic
Keywords: Genomic sequencing
Transcriptome sequencing
Epigenetics
Metabonomics
Immunohistochemical
Multi-omics Study
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2020-12-09
Enrollment: 100
Sex: MALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with primary metastatic prostate cancer are potentially eligible for the current study.

Brief summary: The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Detailed description: Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Eligibility criteria: Inclusion Criteria:

* Pathological confirmation of prostate cancer
* Age: ≥40 years old
* Bone or visceral metastatic disease confirmed by image examination.
* Written informed consent

Exclusion Criteria:

* Patients harbouring other types of cancer besides prostate cancer

Primary outcomes:
measure: Genetic profiling results
timeFrame: From baseline (initial diagnosis of PCa), until study completion (48 months)
measure: Transcriptional profiling results
timeFrame: From baseline (initial diagnosis of PCa), until study completion (48 months)
measure: Epigenomic profiling results
timeFrame: From baseline (initial diagnosis of PCa), until study completion (48 months)
Secondary outcomes:
measure: Protein expression results
timeFrame: From baseline (initial diagnosis of PCa), until study completion (48 months)
Other outcomes:
Locations:
Study officials:
affiliation: West China Hospital
name: Hao Zeng, Dr.
role: PRINCIPAL_INVESTIGATOR
References: